Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D002214:Capsules; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D000077340:Fluvastatin; D006207:Half-Life; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D007211:Indoles / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013607:Tablets; D013997:Time Factors
D002214:Capsules; D003692:Delayed-Action Preparations; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D013607:Tablets; D000077340:Fluvastatin